Circulating tumor DNA, a potential biomarker from solid tumors monitor to anticancer therapies
作者单位：Institute of Translational MedicineNational and Local Joint Engineering Laboratory of High-through Molecular Diagnostic Technologythe First People's Hospital of ChenzhouUniversity of South China Center for Pathologythe First People's Hospital of ChenzhouSouthern Medical University Department of Clinical PharmacologyXiangya Hospital and Institute of Clinical PharmacologyCentral South University and Hunan Key Laboratory of Pharmacogenetics Department of Dermatologythe First People's Hospital of ChenzhouSouthern Medical University
会议名称：《2017年中国肿瘤标志物学术大会暨第十一届肿瘤标志物青年科学家论坛》
会议日期：2017年
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
关 键 词：ctDNA liquid biopsy tumor precise therapy
摘 要：Circulating tumor DNA(ctDNA) in peripheral blood is a liquid biopsy target that contains representative tumor information including gene mutations. ctDNA is a promising new avenue for real-time monitoring of tumor progression. As a non-invasive biomarker and potential surrogate for the entire tumor genome, it has been applied to the detection of driver gene mutations and epigenetic alteration and monitoring of tumor burden, acquired resistance, tumor heterogeneity and early diagnosis. Since precise therapy is a strategy that optimal therapy is decided based on simultaneous tumor genome information, ctDNA may help to perform dynamic genetic surveillance. Dynamic marker surveillance may provide critical information to identify disease progression and guide therapeutic options. This review provides an overview on related articles about ctDNA, with a focus on monitoring response of solid tumors to anticancer therapies.